5 CONCLUSIONI
5.2 RIFLESSIONI FINALI
Questo studio evidenzia come ci sia una discrepanza tra i quattro fenotipi di PCOS, sottolineando in maniera evidente che il fenotipo A risponde peggio alla stimolazione ovarica. Tuttavia, data la natura retrospettiva dello studio e il numero limitato di pazienti, sono necessari ulteriori studi randomizzati per confermare i nostri risultati. In ogni caso, si può affermare che è fondamentale individuare, nelle pazienti PCOS, durante la fase diagnostica l’appartenenza ad uno specifico fenotipo. In tal modo sarebbe possibile personalizzare il tipo di stimolazione ovarica a priori ed individuare il percorso più efficace da intraprendere, al fine di ottenere i migliori risultati con il più basso rischio.
B
IBLIOGRAFIAAA., Messinis IE and Templeton. «The importance of follicle stimulating hormone increase for folliculogenesis.» Hum Reprod, 1990: 5:153-156.
Adam H., Balen. «Ovulation induction in the managment of anovulatory polycystic ovary sindrome .» Molecular and Cellular Endocrinology (Elsevier), 2013: 373,77-82. Adams, J et al. «Polycystic ovaries-a common finding in normal women .» Lancet, Apr
1988: 8590.
Ahlgren, M., Källen, B., Rannevik, G.,. «Outcome of pregnancy after clomiphene therapy. .» Acta Obstet. Gyn. Scan. , 1976: 55 (4), 371–375. .
Al-Inany HG, Youssef MA,Aboulghar M,et al. «Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.» Cochrane Database Syst.Rev., 2011.
AM., Fauser BC and Van Heusden. «Manipulation of human ovarian
function:physiological concepts and clinical consequences.» Endocr Rev, 1997: 18:71-106.
Andrea Borini,Filippo Maria Ubaldi. Medicina della Riproduzione Umana. Roma: CIC Edizioni Internazionali, 2010.
Artini, P G, A Fasciani, M Monti, S Luisi, G D’Ambrogio, and A R Genazzani. «Changes in Vascular Endothelial Growth Factor Levels and the Risk of Ovarian
Hyperstimulation Syndrome in Women Enrolled in an in Vitro Fertilization Program.» Fertility and Sterility , September 1998: 560–564.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, et al. «Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.» J Clin Endocrinol Metab , 2006: 91: 4237–45.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, et al. «The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.» Fertil Steril, 2009: 91:456–88.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. «The prev- alence and features of the polycystic ovary syndrome in an unselected pop- ulation.» J
Clin Endocrinol Metab, 2004: 89:2745–9.
Barber, T.M. et al. «Obesity and polycystic ovary syndrome.» Clin Endocrinol , 2006: 65. Bethesda, MD. «Lipid and lipoprotein analysis. .» National Institute of Health
Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. «A meta-analysis of pregnancy outcomes in women with poly- cystic ovary syndrome. .» Hum Reprod Update , 2006: 12:673–83.
Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. «Clomiphene and anti-oestrogens for ovulation induction in PCOS. .» Cochrane Database Syst. Rev. , 2009: 7(4) . C., Chen. «Pregnancy after human oocyte cryopreservation.» Lancet , Apr 1986: 1:884-
886.
Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. «Phenotypic variation in hy- perandrogenic women influences the findings of abnormal metabolic and
cardiovascular risk parameters .» J Clin Endocrinol Metab , 2005: 29. 90:2545–9 Casadei, L.,Madrigale,A.,Puca,F,Manicuti,C,Emidi,E.,Piccione,e,Dewailly. «The role of
serum anti-mMullerian hormone (AMH) in the hormonal diagnosis of polycystic ovarian syndrome.» Gynecol. Endocrinol., 2013: 29,545-550.
Casper RF, Mitwally MF. «Review: aromatase inhibitors for ovulation
induction.2006;91:760e71. .» The Journal of Clinical Endocrinology and
Metabolism , 2006: 91-760;71.
Cedergren, M.I.,. «Maternal morbid obesity and the risk of adverse pregnancy outcome. .» Obstet. Gynecol. , 2004: 103, 219–224 .
Clark, A.M., Ledger, W., Galletly, C., Tomlinson, L., Blaney, F., Wang, X., Norman, R.J.,. «Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. .» Human Reprod. , 1995: 10, 2705–2712 . Cobo A., Domingo J.,Pérez S,Crescp J.,Remohi,Pellicer A. «Vitrification: an effective
new approach to oocyte banking and preserving fertility in cancer patients.» Clin
Transl Oncol , may 2008: 10:268-273.
Cobo A., Meseguer M, Remohi J., Pellicer A. «Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial.» Hum
Reprod, Sept 2010: 25:2239-2246.
Cooper, Trevor G, Elizabeth Noonan, Sigrid von Eckardstein, Jacques Auger, H W Gordon Baker, Hermann M Behre, Trine B Haugen, et al. «“World Health Organization Reference Values for Human Semen Characteristics.” .» Human
Reproduction Update 16, n. 3 (June 2010): 231-245.
Coulam, Cb et al. «Chronic amovulation syndrome and associated neoplasia.» Obstet
Gynecol., Apr 1983: 61(4):403:7.
Daria Lizneva, M.D., Ph.D,a,b,c Larisa Suturina, M.D., Ph.D.,c Walidah Walker, M.P.H.,a Soumia Brakta, M.D.,a Larisa Gavrilova-Jordan, M.D.,a and Ricardo Azziz, M.D., M.P.H., M.B.A.a,d. «Criteria, prevalence, and phenotypes of
polycystic ovary syndrome .» Fertility and Sterility (American Society for Reproductive Medicine, Published by Elsevier Inc. ), July 2016: 13:6.
Daria Lizneva, M.D.,Larisa Suturina. “Criteria, prevalence,and phenotypes of polycystic ovary syndrome.” 2016.
Das, M.,Gillott,D.J.,et al. «Anti-Müllerian hormone is increased in follicular fluid from unstimulated ovaries in woman with PCOS.» Hum.Reprod., 2008: 23,2122-2126. De Vos A, Van de Velde H,Joris H et al. «In vitro matured metaphase-I oocytes have a
lower fertilization rate but similar embryo quality as mature metaphase-II oocytes after intracytoplasmic sperm injection.» Human Reproduction, 1999: 14,1859- 1863.
Deepika Garg, Reshef Tal. «The role of AMH in the pathophysiology of polycystic avarian syndrome.» Reproductive BioMedicine Online (Elsevier), 20016: 33,15- 28.
Deepika Krishna, Snehal Dhoble,Gautham Praneesh,Suvarna Rathore, Amit
Upadhaya,and Kamini Rao. «Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic:A Randomized control trial.» Journal of Human
Reproductive Sciences, 2016: 9(3):164-172.
Delvigne A, Rozenberg S. «Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS):a review.» Hum Reprod Update, 2002: 8:559-77.
Diamanti-Kandarakis E, Dunaif A. «Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. .» , 2012: 33:981–1030.
E., Carmina. «High Prevalence of Polycystic Ovary Syndrome in Women with Hyrsutism and no other significant clinical Symptoms.» Fert. Steril, 2009: 91.
Eldar-Geva, T.,Margalioth,E.J.,Gal,M.,Ben-Chetrit et al. «Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrtogenism.» Hum.Reprod., 2005: 20,1814- 1819.
Enrico Carmina, MD, MD Anna Campagna, MD Franca Fruzzetti, e MD Rogerio A.Lobo. «AMH measurement versus ovarian ultrasound in the diagnosis of plycystic ovary syndrome in different phenotypes.» Endocrine Practice 22, n. 3 (March 2016): 287-292.
Escobar-Morreale, H.F. et al. «Obesity and the polycystic ovary syndrome.» Minerva
ESHRE/ASRM, Rotterdam. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 2004.
Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
Hum Reprod, 2004. 19:41–7.
EY., Adashi. «Clomiphene citrate: mechanism(s) and site(s) of action – a hypothesis revisited.» Fertil. Steril., 1984: 42(3), 331–344.
EY., Adashi. «Clomiphene citrate: mechanism(s) and site(s) of actionea hypothesis revisited.» Fertility & Sterility , 1984: 42;331;44.
Fariba Ramezanali, Mahnaz Ashrafi,Mandana Hemat,Arezoo Arabipoor,Samaneh Jalali,Ashraf Moini. «Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes:the predictive value of anti-mullerian hormone.» Reproductive Biomedicine Online, 2016: 32,503-512.
Filicori M, Santoro N, Merriam GR, Crowley WF Jr. «Characterization of the
physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle.» J Clin Endocrinol Metab, 1986: 62:1136-44.
Fleming R, Conaghan C and Coutts JR. «The uses of LH-releasing hormone and analogs in inferility.» Ir Med Sci, 1986: 155:22-29.
Ford WC, North K,Taylor H,Farrow A,Hull MG,Golding J. «Increasing paternal age is associated with delayed conception in a large population of fertile
couples:evidence for declining fecundity in older men.» Hum Reprod, 2000: 15,1703-1708.
Fox, R et al. «Ultrasound diagnosis of polycystic ovaries .» Ann NY Acad sci , May 1993: 28;687:217-23.
GD, Hodgen. «The dominant ovarian follicle.» Fertil Steril, 1982: 38:281-300. Gd, Oehninger S and hodgen. «Induction of ovulation for assisted reproduction
programmes.» Baillieres Clin Obstet Gynaecol , 1990: 4:541-573. Georgopoulos NA, Papadakis E, Armeni AK, Katsikis I, Roupas ND, Panidis D.
«Elevated serum androstenedione is associated with a more se- vere phenotype in women with polycystic ovary syndrome (PCOS) .» Hor- mones (Athens) , 2014: 13:213–21 .
Group, Thessaloniki Eshre/Asrm-Sponsored Pcos Consensus Workshop. «Consensus on infertility treatment related to polycystic ovary syndrome .» Hum. Reprod. , 2008: 23(3), 462–477.
group, Thessaloniki Eshre/Asrm-Sponsored pcos consensus workshop. «Consensus on infertility treatment related to polycystic ovary syndrome.» Hum.Reprod. 23, n. 3 (2008): 462-477.
Hall JE, Schoenfeld DA, Martin KA, Crowley-WF. «Hypotalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal- follicular transition.» Clin Endocrinol Metab, 1992: 74:600-7.
Hamilton-Fairley, D., Kiddy, D., Watson, H., Paterson, C., Franks, S. «Association of moderate obesity with poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotropins. .» Brit. J. Obstet. Gynaecol. , 1992: 99, 128–131. .
Harborne LR, Sattar N, Norman JE, et al. «Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. .» The Journal of Clinical
Endocrinology and Metabolism , 2005: 90:495;8.
Health, National Institutes of. Evidence-based methodology workshop on polycystic ovary
syndrome . 2016. https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf
Homburg R, Hendriks ML, Konig TE. «Clomifene citrate or low-dose FSH for the first- line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. .» Hum. Reprod. , 2012: 27(2), 468–473 .
Homburg R, Hendriks ML, Konig TE, et al. «Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with
polycystic ovary syndrome: a prospective randomized multinational study. .»
Hum Reprod, 2012: 27-468;73.
Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P and Collins JA. «The routine use of gonadotropin-releasing hormone agonists prior to in vitro
fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials .» Fertil Steril , 1992: 58:888-896.
Huirne JA, Lamabalk CB, Van Loenen AC, Schats R., Hompes PG, Fauser BC and Macklon NS. «Contemporary pharmacological manipulation in assisted reproduction.» Drugs, 2004: 64:297-322.
Humaidan P, Kol S, Papanikolau EG. Copenhagen GnRH Agonist Triggering Workshop Group. «GnRH agonist for triggering of final oocyte maturation: Time for a change of practice?» Hum Reprod Update, 2011: 17:510-24.
Humanaid P, Alsbjerg B. «GnRH trigger for final oocyte maturation:IS HCG trigger history?» Reprod Biomed Online, 2014: 29:274-80.
Itskovitz J, Boldes R.,Barlev A, Erlik Y,Kahana L,Brandes JM. «the induction of LH surge and oocyte maturation by GnRH analogue (Buserelin), in women
undergoing ovarian stimulation for in vitro fertilization.» Gynecol Endocrinol., 1988: 2:165.
J., Gougeon A and Testart. «Influence of human menopausal gonadotropin on the recruitment of human ovarian follicles.» Fertil Steril, 1990: 54:848-852. JE., Nestler. «Inositolphosphoglycans (IPGs) as mediators of insulin’s steroidogenic
actions. .» J. Basic Clin. Physiol. Pharmacol. , 1998: 9(2–4), 197–204. Johansson K, Cnattingius S, Naslund I, et al. «Outcomes of pregnancy after bariatric
surgery.» The New England Journal of Medicine, 2015: 372:814;24.
Kettel LM, Roseff SJ, Berga SL, Mortola JF, Yen SS. «Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. .»
Fertil. Steril., 1993: 59(3), 532–538 .
Kjerulff LE, Sanchez-Ramos L, Duffy D. « Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis.» Am J Obstet Gynecol , 2011: 204:558.e1–6.
Klipstein S, Reindollar RH, Regan MM and Alper MM. «Initiation of the gonadotropin- releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm.» Fertil Steril, 2004: 81:714-715.
Kol S, Homburg R, Alsbjerg B, Humaidan P. «The gonadotropin-releasing hormone antagonist protocol – the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. .» Acta. Obstet. Gynecol.
Scand., 2012: 91(6), 643–647 .
Laven, J.S.,Mulders,A.G.,Visser,J.A.,,Themmen,A.P.,De Jong. «Anti-müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.» J.Clin.Endocrinol.Metab., 2004: 89,318-323.
Le Nestour E, Marraoui J, Lahlou N Roger M, De Ziegler D and Bouchard P. «The role of estradiol in the rise in the follicle stimulation hormone levels during the luteal- follicular transition.» J Clin Endocrinol Metab, 1993: 77:439-442.
Lu, Wenyan Xi & Fei Gong & Guangxiu. «Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients .» J Assist Reprod
Genet , 2012: 29:397–402 .
Ludwig M, Doody Km. «Use of recombinant human chorionic gonadotropin in ovulation induction .» Fertil Steril, 2003: 79:1051-1059.
Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM and Diedrich K. «Tailoring the GnRH antagonist cetrorelix acetate to individual patients' need in
ovarina stimulation for IVF: results of a prospective, randomized study .» Hum
Reprod, 2002: 17:2842-2845.
M.M.Biljan, R. Hemmings,N. Brassard. «The oucome of 150 babies following the treatment with letrozole or letrozole and gonadotropins.» St Mary's Hospital, Montreal Fertility centre, Montreal.
Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. «The predictive value of circulating anti-Müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. .» J. Clin. Endocrinol. Metab. , 2013: 98(10), 4170–4175.
Massague, J.,Chen,Y.G. «Controlling TGF-beta signaling.» Genes Dev., 2000: 14,627- 644.
Matikainen T, Ding YQ, Vergara M, Huhtaniemi I, Couzinet B and Schaison G.
«Differing responses of plasma bioactive and immunocreative follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.» J Clin Endocrinol Metab, 1992: 75:820-825.
MD, Barbieri RL and Hornstein. «Assisted reproduction in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues.» Endocr Rev, 1999: 20:249-252.
Moran, L.J., Hutchison, S.K., Norman, R.J., Teede, H.J.,. «Lifestyle changes in women with polycystic ovary syndrome. .» Cochrane Database Syst. Rev. , 2011: 16 (2). Nestler JE, Jakubowicz DJ, Reamer P, et al. «Ovulatory and metabolic effects of d-chiro-
inositol in the polycystic ovary syndrome. .» England Journal of Medicine, Apr 1999: 29;340:1314;20.
Nestler JE, Jakubowicz DJ. «Decreases in ovarian cytochrome P450C17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. .» The New England Journal of Medicine , 1996: 335:617;23. NestlerJE, JakubowiczDJ,EvansWS,etal.
«Effectsofmetforminonspontaneousandclomiphene-inducedovulationinthe polycystic ovary syndrome. .» The New England Journal of Medicine, 1998: 338:187;80.
Noguiera D, Staessen C,Van de Velde H et al. «Nuclear status and cytogenetics of embryos derived from vitro-matured oocytes.» Fertility and Sterility, 2000: 74(2), 295-298.
transfer: a dose finding study of 3 versus 2 mg .» Hum Reprod, 1998: 13:2411- 2414.
Orio, F. et al. «Cardiovascular risk in woman with polycystic ovary sindrome.» fertil
Steril , Jul 2006: 1:S20-1.
Ortiz ME, Salvatierra AM,Lopez J et al. «Postovulatory aging of human ova.I. Light microscopy observations.» Gamete Res., 1982: 6,11-17.
P., Fauser BC and Devroey. «Reproductive biology and IVF:ovarian stimulation and luteal phase consequences.» Trends Endocrinol Metab, 2003: 14:236-242. P., Humaidan. «Luteal phase rescue in high-risk OHSS patients by GnRH agonist
triggering in combination with low-dose HCG:a pilot study.»
Reprod.Biomed.Online, 2009: 18(5),630-634.
P.G.Artini, O.M.DI Berardino,F.Papini,A.D.Genazzani,G.Simi,M.Ruggiero,and V.Cela. «Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.» Gynecological Endocrinology, 2013:
29(4);375-379.
Paolo Giovanni Artini, M.E.Obino, A.Uccelli,E.Carletti,E.Casarosa,C.Tatone,V.Cela. «Maintenance of biologiocal competence after oocyte vitrification.»
Parahuleva, N.,Pehlivanov,B.,Orbecova,M. «Anti-Mullerian hormone in the major phenotypes of polycystic ovary sindrome.» Akush. Ginekol., 2014: 53,22-27. Park, H.T.,Cho,G.J.,Ahn,K.H.,Shin,J.H.,Kim,Y.T.,Hur,J.Y.,Kim,S.H.,Lee,K.W.Kim,T.,.
«Association of insulin resistance with anti-Mullerian hormone levels in women with out PCOS.» Clin.Endocrinol.(Oxf), 2010: 72,26-31.
Pellat, L.,Hanna,L.,Brincat,M.,Galea,R. «Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries.» J.Clin.Endocrinol.Metab, 2007: 92,240-245.
Pigny, P.,Merlen:E.,Robert,Y.,Cortet-Rudelli,C.,Decanter,C.,JONARD,S.,Dewailly,D.,. «Elevated serum level of anti-Mullerian hormone in patients with
PCOS:relationship to the ovrian follicle excess and to the follicular arrest.»
J.Clin.Endocrinol.Metab., 2003: 88,5957-5962.
Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, Jarvela I, Ruokonen A, et al. «Unfavorable hormonal, metabolic, and inflammatory al- terations persist after menopause in women with PCOS. .» J Clin Endocrinol Metab , 2011: 96:1827– 34.
Rajpert-De Meyts, E.,Jorgensen et al. «Expression of anti-Müllerian hormone during normal and pathological gonadal development:association with differentiation of Sertoli and granulosa cells.» L.Clin.Endocrinol.Metab., 1999: 84,3836-3844.
Reshef Tal, MD,PhD, MD David B.Seifer, BA Moisey Khanimov, PhD Henry E.Malter, MD Richard V.Grazi, e MD,PhD Ben Leader. «Characterization of women with elevated antimullerian hormone levels (AMH):correlation of AMH with
polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes .» American Journal of Obstetrics&Gynecology, April 2014: 4:39. Richard S. Legro, M.D. «Ovulation induction in polycystic ovary syndrome: Current
options .» Best Practice & Research Clinical Obstetrics and Gynaecology (Elsevier), 2016: 152-159.
RJ., Chang. «A practical approach to the diagnosis of polycystic ovary syndrome.» Am J
Obstet Gynecol , 2004: 81:19-25.
Rodin, A. et al. «Hyperandrogenism in polycystic ovary syndrome. Evidence of
dysregulation of 11 beta-hydroxysteroid dehydrogenase.» N Engl J Med , 1994: 330.
Rosencrantz MA, Coffler MS, Haggan A, Duke KB, Donohue MC, Shayya RF, et al. «Clinical evidence for predominance of delta-5 steroid pro- duction in women with polycystic ovary syndrome .» J Clin Endocrinol Metab , 2011: 96:1106–13. SA, Butler. «hCG-mass units,molar conversions, and the standardization of biologic
units.» Fertil Steril, 2003: 80:1533-1534.
Samer Tannus. Yechiel z., Burke & Shahar Kol. «Treatment strategies for the infertile polycystic ovary syndrome patient.» Women's Healt, 2015: 11(6),901-912. Sandrine Chamayou, Antonino Guglielmino. «Selezione morfologica e funzionale
dell'ovocita.» In Medicina della Riproduzione Umana, di Filippo Maria Ubaldi Andrea Borini, 393-396.
Sharma S, Ghosh S, Singh S et al. «Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. .» PLoS ONE , 2014: 9(10).
Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. «Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. .» J Clin
Endocrinol Metab , 2008: 93:1276–84.
Shokeir T, El-Kannishy G. «Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: factors associated with clinical response. .» J.
Womens Health (Larchmt) , 2008: 17(9), 1445–1452.
syndrome? A structured literature review .» Fertil. Steril., 2006: 86(5), 1432– 1437.
T.Shavit, A.Ellenbogen,M.Michaeli,E.Kartchovsky,O.Ruzov,E.Shalom-Paz. «In-vitro maturation of oocytes vs in vitro fertilization with a gonadotropin-releasing hormone antagonist for women with PCOS:can superiority be defined?»
European Journal of Obstetrics & Gynecology and Reproductive Biology
(Elsevier), 2014: 179,46-50.
Tal, R,Seifer,D.B. et al. «Characterization of women with elevated antimullerian hormone levels (AMH):correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.»
Am.J.Obstet.Gynecol. 211,e1-e8.
Tang T, Lord JM, Norman RJ, et al. «Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. .» Cochrane Database Syst Rev 2012; CD003053., 5:.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. «Insulin- sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility .» Cochrane
Database Syst. Rev. , 2012: 16(5).
Technology, The Practise Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive. «Mature oocyte cryopreservation: a guideline.» Fertility and Sterility, 2008.
Tiras, MB. et al. «Alteration in cardiac flow parameters in patients with polycystic ovary syndrome .» Hum Reprod., 1999: 14.
Tresoldi, Giorgio. «La sindome dell'ovaio policistico.» Rivista della Società Italiana di
Medicina Generale (SIMG, Milano) 6 (Dicembre 2009): 30,18:25.
Unfer V, Carlomagno G, Dante G, Facchinetti F. «Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. .» Gynecol.
Endocrinol. , 2012: 28(7), 509–515.
Vugnesh, J.P. et al. «Polycystic ovary syndrome: a component of metabolic syndrome?» (L Postgrad Med) Apr-Jun 2007: 128-34.
Yen SS, Llerena O,LittleB,Pearson OH. «Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man.» J Clin Endocrinol Metab., 1968: 28:1763-7.
Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. «Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diag- nostic criteria.» Hum Reprod, 2012: 27:3067–73. .
Zawadzki JK, Dunaif A. «Diagnostic criteria for polycystic ovary syndrome; to- wards a rational approach .» (Dunaif A, Givens JR, Haseltine F, Merriam G, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific) 1992.
Zeleznik AJ, Hillier SG. «The role of gonadotropins in the selection of the preovulatory follicle.» Clin Obstet Gynecol, 1984: 27:927-40.